Fiche publication
Date publication
mai 2026
Journal
Diabetes & metabolism
Auteurs
Membres identifiés du Cancéropôle Est :
Pr VERGES Bruno
Tous les auteurs :
Caussy C, Vergès B, Subtil F, Abichou-Klich A, Hervieu V, Leleu D, Milot L, Ségrestin B, Bin S, Berthiller J, Rouland A, Delaunay D, Primot C, Hadjadj S, Cariou B, Moulin P, Charrière S, Disse E
Lien Pubmed
Résumé
Patients with type 2 diabetes (T2D) and obesity are at increased risk of metabolic dysfunction-associated steatotic liver disease (MASLD) with advanced fibrosis (AF), requiring systematic non-invasive assessment using liver stiffness measurement (LSM) or the ELF test. However, access to these biomarkers remains limited in diabetology. We therefore evaluated the diagnostic performance of a new point-of-care ultrasound device, Hepatoscope, for the risk stratification of AF.
Mots clés
Diabetology, MASH, MASLD, Screening, Transient elastography
Référence
Diabetes Metab. 2026 05 8;52(4):101766
